KAPOSI'S SARCOMA RESPONSE CRITERIA
Ellen G. Feigal(National Cancer Institute), R. Wittes(National Institutes of Health), Richard S. Ungerleider(Unknown), Robert Justice(United States Food and Drug Administration), Robert Yarchoan(National Cancer Institute), Anthony J. Murgo(National Cancer Institute), Susan E. Krown(Memorial Sloan Kettering Cancer Center), James M. Pluda(Center for Cancer Research), Jamie Von Roenn(Northwestern University), Susan G. Arbuck(National Cancer Institute), Martin G. McCabe(Manchester Academic Health Science Centre)
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology
April 1, 1997
Cited by 3
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
|Journal of Clinical Oncology|2002|531